Newcastle Disease Virus Vector-Based SARS-CoV-2 Vaccine Candidate AVX/COVID-12 Activates T Cells and Is Recognized by Antibodies from COVID-19 Patients and Vaccinated
Authors:
- Alejandro Torres-FloresATAlejandro Torres-Flores
- Luis Alberto Ontiveros-PadillaLuis Alberto Ontiveros-Padilla
- Ruth Lizzeth Madera-SandovalRuth Lizzeth Madera-Sandoval
- Araceli Tepale-SeguraATAraceli Tepale-Segura
- Julián Gajón-MartínezJGJulián Gajón-Martínez
- Tania Rivera-HernándezTRTania Rivera-Hernández
- Eduardo Antonio Ferat-OsorioEFEduardo Antonio Ferat-Osorio
- Arturo Cérbulo-VázquezACArturo Cérbulo-Vázquez
- Lourdes Andrea Arriaga-PizanoLALourdes Andrea Arriaga-Pizano
- Laura BonifazLBLaura Bonifaz
- Georgina Paz-De la RosaGRGeorgina Paz-De la Rosa
Preprint
Abstract
Several effective vaccines for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed and implemented in the population. However, the current production capacity falls short of meeting global demand. Therefore, it is crucial to further develop novel vaccine platforms that can bridge the distribution gap. AVX/COVID-12 is a vector-based vaccine that utilizes the Newcastle Disease virus (NDV) to present the SARS-CoV-2 spike protein to the immune system. This study analyses the antigenicity of the vaccine candidate by examining antibody binding and T-cell activation in individuals infected with SARS-CoV-2 or variants of concern (VOCs), as well as in healthy volunteers who received coronavirus disease 2019 (COVID-19) vaccinations. Our findings indicate that the vaccine effectively binds antibodies and activates T-cells in individuals who received 2 or 3 doses of BNT162b2 or AZ/ChAdOx-1-S vaccines. Furthermore, the stimulation of T-cells from patients and vaccine recipients with AVX/COVID-12 resulted in their proliferation and secretion of interferon-gamma (IFN-γ) in both CD4+ and CD8+ T-cells. In conclusion, the AVX/COVID-12 vectored vaccine candidate demonstrates the ability to stimulate robust cellular responses and is recognized by antibodies primed by the spike protein present in SARS-CoV-2 viruses that infected patients, as well as in the mRNA BNT162b2 and AZ/ChAdOx-1-S vaccines. These results support the inclusion of the AVX/COVID-12 vaccine as a booster in vaccination programs aimed at addressing COVID-19 caused by SARS-CoV-2 and its VOCs.Keywords
This publication has 27 references indexed in Scilit:
- Interim safety and immunogenicity results from an NDV-based COVID-19 vaccine phase I trial in Mexiconpj Vaccines, 2023
- Quantifying the local adaptive landscape of a nascent bacterial communityNature Communications, 2023
- Prevalent and immunodominant CD8 T cell epitopes are conserved in SARS-CoV-2 variantsCell Reports, 2023
- Bioinformatic Analysis of B- and T-cell Epitopes from SARS-CoV-2 Structural Proteins and their Potential Cross-reactivity with Emerging Variants and other Human CoronavirusesArchives of Medical Research, 2022
- Immunogenicity and protective efficacy of an intranasal live-attenuated vaccine against SARS-CoV-2iScience, 2021
- Profiling B cell immunodominance after SARS-CoV-2 infection reveals antibody evolution to non-neutralizing viral targetsImmunity, 2021
- Native-like SARS-CoV-2 Spike Glycoprotein Expressed by ChAdOx1 nCoV-19/AZD1222 VaccineACS Central Science, 2021
- Perineuronal nets stabilize the grid cell networkNature Communications, 2021
- Loss of Bcl-6-Expressing T Follicular Helper Cells and Germinal Centers in COVID-19Cell, 2020
- Recombinant Newcastle Disease Virus as a Vaccine Vector for Cancer TherapyMolecular Therapy, 2008